This slide presentation includes forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: our expected revenues and net profit related to sales of our COVID-19 vaccine, referred to as COMIRNATY® in the United States and European Union as approved or authorized for use under conditional marketing approval, in territories controlled by our collaboration partners, particularly for those figures that are derived from preliminary estimates provided by our partners; our pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after our initial sales to national governments; the extent to which a COVID-19 vaccine continues to be necessary in the future; competition from other COVID-19 vaccines or related to our other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the rate and degree of market acceptance of our COVID-19 vaccine and our investigational medicines, if approved; the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; the timing of and our ability to obtain and maintain regulatory approval for our product candidates; the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine (including a potential booster dose of BNT162b2 and/or a potential booster dose of a variant of BNT162b2 having a modified mRNA sequence); the ability of BNT162b2 to prevent COVID-19 caused by emerging virus variants; our ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of our third-party collaborators to continue research and development activities relating to our development candidates and investigational medicines; the impact of the COVID-19 pandemic on our development programs, supply chain, collaborators and financial performance; unforeseen safety issues and claims for personal injury or death arising from the use of our COVID-19 vaccine and other products and product candidates developed or manufactured by us; BioNTech’s Malaria, Tuberculosis and HIV programs; timing for selecting clinical candidates for these programs and the commencement of a clinical trial, as well as any data readouts; the nature of the collaboration with the African Union and the Africa CDC; the nature and duration of support from WHO, the European Commission and other organizations with establishing infrastructure; the development of sustainable vaccine production and supply solutions on the African continent and the nature and feasibility of these solutions; our estimates of research and development revenues, commercial revenues, cost of sales, research and development expenses, sales and marketing expenses, general and administrative expenses, other operating income less expenses, finance income less expenses, income taxes, shares outstanding and basic and diluted profit for the period per share and our needs for or ability to obtain additional financing; our ability to identify, recruit and retain key personnel; our and our collaborators’ ability to protect and enforce our intellectual property protection for our proprietary and collaborative product candidates, and the scope of such protection; the development of and projections relating to our competitors or our industry; our ability and that of our collaborators to commercialize and market our product candidates, if approved, including our COVID-19 vaccine; the amount of and our ability to use net operating losses and research and development credits to offset future taxable income; our ability to manage our development and expansion; regulatory developments in the United States and foreign countries; our ability to effectively scale our production capabilities and manufacture our products, including our target COVID-19 vaccine pre-duction levels, and our product candidates; our ability to implement, maintain and improve effective internal controls; our plans for expansion in southeast Asia and China, including our planned regional headquarters and manufacturing facility in Singapore as well as the joint venture with Fosun Pharma; and other factors not known to us at this time. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this quarterly report are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You should review the risks and uncertainties described under the heading “Risk Factors” in this quarterly report and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at https://www.sec.gov/. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this quarterly report in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech’s current expectations and speak only as of the date hereof.
Safety Information

Indication & Authorized Use:
COMIRNATY® (COVID-19 vaccine, mRNA) is an FDA-approved COVID-19 vaccine made by Pfizer for BioNTech.

- It is approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older
- It is also authorized under Emergency Use Authorization (EUA) to be administered for emergency use to: prevent COVID-19 in individuals 12 through 15 years, and provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise

The Pfizer-BioNTech COVID-19 vaccine has received EUA from FDA to:
- prevent COVID-19 in individuals 12 years of age and older, and
- provide a third dose to individuals 12 years of age and older who have been determined to have certain kinds of immunocompromise

The FDA-approved COMIRNATY® (COVID-19 vaccine, mRNA) and the EUA-authorized Pfizer-BioNTech COVID-19 vaccine have the same formulation and can be used interchangeably to provide the COVID-19 vaccination series. An individual may be offered either COMIRNATY® (COVID-19 vaccine, mRNA) or the Pfizer-BioNTech COVID-19 Vaccine to prevent coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2.

Important Safety Information:
- Individuals should not get the Pfizer-BioNTech COVID-19 vaccine if they: had a severe allergic reaction after a previous dose of this vaccine, had a severe allergic reaction to any ingredient of this vaccine
- Individuals should tell the vaccination provider about all of their medical conditions, including if they: have any allergies, have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation of the lining outside the heart), have a fever, have a bleeding disorder or are on a blood thinner, are immunocompromised or are on a medicine that affects the immune system, are pregnant, plan to become pregnant, or are breastfeeding, have received another COVID-19 vaccine, have ever fainted in association with an injection
- The vaccine may not protect everyone.
- Side effects reported with the vaccine include:
- A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose of the vaccine. For this reason, vaccination providers may ask individuals to stay at the place where they received the vaccine for monitoring after vaccination
- Signs of a severe allergic reaction can include difficulty breathing, swelling of the face and throat, a fast heartbeat, a bad rash all over the body, dizziness, and weakness
- If an individual experiences a severe allergic reaction, they should call 9-1-1 or go to the nearest hospital
- Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within a few days following receipt of the second dose of the vaccine. The chance of having this occur is very low. Individuals should seek medical attention right away if they have any of the following symptoms after receiving the vaccine: chest pain, shortness of breath, feelings of having a fast-beating, fluttering, or pounding heart
- Side effects that have been reported with the vaccine include: severe allergic reactions; non-severe allergic reactions such as rash, itching, hives, or swelling of the face; myocarditis (inflammation of the heart muscle); pericarditis (inflammation of the lining outside the heart); injection site pain; tiredness; headache; muscle pain; chills; joint pain; fever; injection site swelling; injection site redness; nausea; feeling unwell; swollen lymph nodes (lymphadenopathy); diarrhea; vomiting; arm pain
- These may not be all the possible side effects of the vaccine. Serious and unexpected side effects may occur. The vaccine is still being studied in clinical trials. Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away
- There is no information on the use of the vaccine with other vaccines.

Patients should always ask their healthcare providers for medical advice about adverse events. Individuals are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967. In addition, side effects can be reported to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.
COMIRNATY® ▼ (the Pfizer-BioNTech COVID-19 vaccine) has been granted conditional marketing authorisation by the by the European Commission to prevent coronavirus disease 2019 (COVID-19) in people from 12 years of age. The European Medicines Agency’s (EMA’s) human medicines committee (CHMP) has completed its rigorous evaluation of COMIRNATY®, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available.

Important safety information

- Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine.
- Very rare cases of myocarditis and pericarditis have been observed following vaccination with Comirnaty. These cases have primarily occurred within 14 days following vaccination, more often after the second vaccination, and more often in younger men. Available data suggest that the course of myocarditis and pericarditis following vaccination is not different from myocarditis or pericarditis in general.
- Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions (e.g. dizziness, palpitations, increases in heart rate, alterations in blood pressure, tingling sensations and sweating) may occur in association with the vaccination process itself. Stress-related reactions are temporary and resolve on their own. Individuals should be advised to bring symptoms to the attention of the vaccination provider for evaluation. It is important that precautions are in place to avoid injury from fainting.
- The efficacy, safety and immunogenicity of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of COMIRNATY® may be lower in immunosuppressed individuals.
- As with any vaccine, vaccination with COMIRNATY® may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their second dose of vaccine.
- In clinical studies, adverse reactions in participants 16 years of age and older were injection site pain (> 80%), fatigue (> 60%), headache (> 50%), myalgia and chills (> 30%), arthralgia (> 20%), pyrexia and injection site swelling (> 10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age.
- The overall safety profile of COMIRNATY® in adolescents 12 to 15 years of age was similar to that seen in participants 16 years of age and older. The most frequent adverse reactions in clinical trial participants 12 to 15 years of age were injection site pain (> 90%), fatigue and headache (> 70%), myalgia and chills (> 40%), arthralgia and pyrexia (> 20%).
- There is limited experience with use of COMIRNATY® in pregnant women. Administration of COMIRNATY® in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and fetus.
- It is unknown whether COMIRNATY® is excreted in human milk.
- Interactions with other medicinal products or concomitant administration of COMIRNATY® with other vaccines has not been studied.
- For complete information on the safety of COMIRNATY® always make reference to the approved Summary of Product Characteristics and Package Leaflet available in all the languages of the European Union on the EMA website.

The black equilateral triangle denotes that additional monitoring is required to capture any adverse reactions. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Side effects can be reported to EudraVigilance [http://www.adrreports.eu/] or directly to BioNTech using email medinfo@biontech.de, telephone +49 6131 9084 0, or our website https://medicalinformation.biontech.de/
Next generation Immunotherapy

Harnessing the full potential of the immune system

- Building a fully integrated biopharmaceutical company
- Immunotherapies for cancer & infectious diseases and beyond
- Broad suite of novel technologies
- Industry-leading global collaborations
Transformed Into a Fully Integrated, Global Immunotherapy Company

**Fully Integrated Structure**

- Deep Immunology Expertise
- Broad Suite of Novel Technologies
- Bioinformatics Approach
- In-House Manufacturing
- Commercial Capabilities
- Global Team of 2,500+

**A Robust Pipeline of 20+ Candidates**

Next-Gen Immunotherapies & Vaccines
Oncology, Infectious Disease and Beyond

Accelerated by Proven Execution and COVID-19 Vaccine Cash Flow

Potential to Launch Multiple Products in Next 5 Years
mRNA Technology Poised to Revolutionize Immunotherapy

**Today**

mRNA vaccines established as a **New Drug Class**

- **BNT162b2**

Diversification and maturation of our mRNA technology enabled the accelerated development of our COVID-19 vaccine

**Tomorrow**

mRNA technology potential to **Displace Traditional Modalities**

- mRNA infectious disease vaccines
- mRNA cancer vaccines
- CAR-T cell amplifying mRNA vaccine
- Systemic mRNA encoded immuno-therapies

**The Future**

mRNA potential to open up new opportunities **Beyond the Horizon**

- Autoimmune diseases
- Allergy
- Inflammation
- Regenerative medicine
- Other therapeutic areas

Broad IP portfolio covering technologies, targets and formulations. Deep expertise and know-how built over the course of more than a decade.
# Infectious Diseases: A Long-term Growth Pillar

<table>
<thead>
<tr>
<th>mRNA vaccines to combat major global health burden</th>
<th>Opportunity to impact infectious diseases with high unmet need</th>
<th>BNT161 influenza vaccine candidate designed to improve traditional vaccines</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Malaria</strong>&lt;sup&gt;1&lt;/sup&gt;:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Development of first mRNA-based Malaria vaccine recently started</td>
<td>• Up to 10 mRNA vaccine candidates in preclinical development&lt;sup&gt;3&lt;/sup&gt;</td>
<td>• First patient dosed in Phase 1 trial</td>
</tr>
<tr>
<td>• Implementation of sustainable end-to-end vaccine supply solutions in Africa planned</td>
<td></td>
<td>• Eligible for milestone payments and royalties through Pfizer agreement</td>
</tr>
<tr>
<td><strong>HIV and tuberculosis</strong>&lt;sup&gt;2&lt;/sup&gt;:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Preclinical development of multiple product candidates ongoing</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup> Collaboration with kENUP Foundation; <sup>2</sup> Collaboration with Bill & Melinda Gates Foundation; <sup>3</sup> University of Pennsylvania collaboration
Potential to Tackle Multiple Diseases with Different Therapeutic Modalities

mRNA Cancer Vaccines

iNeST FixVac
- Multi-specificity, multi-valency, high (neo)antigen specific T cell responses with unprecedented potency
- 3 Phase 2 randomized trials (iNeST and 2 FixVac)

Next Generation Immunomodulators

Bispecifics
- Next-generation checkpoint inhibitors to address a broad range of cancers
- Phase 1/2 trials of 2 bi-specific antibodies

Cell Therapies

Next Gen CAR-T Cell / Neoantigen-based T Cell Therapy
- Phase 1 FIH trials started in Feb. and Apr 2021

Antibodies

Targeted Cancer Antibodies
- CA19-9 antibody in 1L pancreatic cancer
- Phase 1/2 trial

Targeting Cancer + Immunomodulation

TLR-7 Agonist
- Potently modulates innate immunity
- Potential for combination with other IO agents
- Phase 1 trial

Small Molecule Immunomodulators

Engineered Biologicals

Ribocytokines
- mRNA encoded cytokines with a prolonged T1/2 and improved safety profile
- Potential to amplify vaccines and CPIs
- Phase 1 FIH trials started in Feb. and Jun. 2021

Oncology: Multiple product opportunities with unique combination potential in clinical testing

CAR, Chimeric antigen receptor; CA 19-9: Cancer antigen 19-9; IO, Immuno-oncology; CPI, Check-point Inhibitor; FIH, First-in-human; TLR-7, Toll-like receptor 7; T1/2, half-life
## A Technology Agnostic Approach Targets a Broader Addressable Cancer Market

<table>
<thead>
<tr>
<th>Cancer segment</th>
<th>Patient Population</th>
<th>Challenge</th>
<th>Our Therapeutic Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>High mutational burden/ adjuvant stage cancers</td>
<td>Significant portion of cancer patients</td>
<td>Poor risk-benefit profile of checkpoint inhibitors</td>
<td>• mRNA Neoantigen Immunotherapy (iNeST)</td>
</tr>
<tr>
<td>Low mutational burden cancers</td>
<td>&gt;60% of cancers</td>
<td>Poor response to checkpoint inhibitors</td>
<td>• Shared Antigens (FixVac, CAR-T cells, Neoantigen-targeted T cells, Antibodies)</td>
</tr>
<tr>
<td>“Immune desert” cancers</td>
<td>&gt;40% of high-mutational cancers</td>
<td>Poor infiltration and activation of T-cells in TME(^1)</td>
<td>• RNA Immunotherapy • Immunostimulatory Compounds (intratumoral, RiboCytokines)</td>
</tr>
<tr>
<td>Cancers with MHC / B2M loss</td>
<td>20-30% of CPI-experienced advanced cancers</td>
<td>Failure of immune system to recognize tumor cells</td>
<td>• Antibodies • CAR-Ts</td>
</tr>
<tr>
<td>Refractory tumors</td>
<td>Patients with large tumors and multiple resistance mechanisms</td>
<td>Few treatment options</td>
<td>• Cell Therapies • Combination Therapies</td>
</tr>
</tbody>
</table>

\(^1\)Tumor microenvironment
Next Wave Oncology Advancing Innovation Beyond Current Boundaries

CARVac
CAR-T cell amplifying mRNA therapy for solid tumors

- BNT211 (CLDN 6 CAR)
  Next generation CAR-T targeting CLDN6 with CARVac

NEOSTIM T cell therapy
Individualized Neoantigen specific T cell therapy

- BNT221
  PBMC derived ex vivo T cell therapy

RiboCytokines
mRNA encoded Cytokines

- BNT151
  (modified IL-2)
- BNT152 + BNT153
  (IL-2/IL-7)

RiboMabs
mRNA encoded Antibodies

- BNT141
  (undisclosed)
- BNT142
  (CD3xCLDN6)

Wholly owned: ✓
FIH start: FPD Feb. 2021

FPD Apr. 2021

BNT151: FPD Feb. 2021
BNT152+BNT153: FPD June 2021

2H 2021

FPD, first patient dosed; CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor T cells; IL-2, interleukin 2; IL-7, Interleukin 7; PBMC, peripheral blood mononuclear cells; FIH, first in human

On Track to Achieve Multiple Significant Data & Clinical Milestones in 2H 2021

Eight Clinical Trial Initiations in 2021, Including Three Randomized Phase 2

5+ Trial Updates

- **BNT162b2**: Multiple updates
- **BNT311**: Bi-specific CPI: PD-L1 x 4-1BB in solid tumors
- **BNT312**: Bi-specific CPI: CD40 x 4-1BB in solid tumors
- **BNT211**: CLDN-6 CAR-T + CARVac in solid tumors
- **BNT411**: TLR-7 agonist +/- CPI in solid tumors

3 Randomized Phase 2 Trial Starts

- **BNT111**: FixVac + CPI in CPI-R/R melanoma
- **BNT113**: FixVac HPV16+ + CPI in 1L HNSCC
- **BNT122**: iNeST (autogene cevumeran) in adjuvant mCRC

7 First-in-human Phase 1 Trial Starts

- **BNT211**: CLDN-6 CAR-T + CARVac in solid tumors
- **BNT221**: NEOSTIM individualized neoantigen-T cell therapy in melanoma
- **BNT151**: Ribocytokine (modified IL-2)
- **BNT152+153**: RiboCytokine IL-7 / IL-2 combo in solid tumors
  - **BNT141**: RiboMab (undisclosed)
  - **BNT142**: RiboMab bi-specific CPI in solid tumors (CD3xCLDN6)
- **BNT161**: Influenza vaccine program

---

PD-L1, programmed death-ligand 1; CLDN6, Claudin-6, CAR-T Cells, Chimeric Antigen Receptor T Cells; IL-2, Interleukin 2; IL-7, Interleukin 7; TLR-7, Toll-like receptor-7 CPI, Check-Point Inhibitor; HNSCC, Head and Neck Squamous Cell Carcinoma; mCRC, Metastatic Colorectal Cancer; iNeST is partnered with Genentech/Roche; BNT311 and BNT312 partnered with Genmab;
Building a 21st Century Global Immunotherapy Powerhouse

Increase global footprint

- New regional headquarters planned in Singapore
- Commercial subsidiaries established in Germany and Turkey
- Offices established in the United States

Expand integrated infrastructure

- Continue investment in innovation to support future product launches
- Invest in clinical, commercial and manufacturing, and digital capabilities
- Attract and retain top talent

Rapidly advance pipeline

- 15 product candidates in oncology in 18 ongoing clinical trials
- 3 potentially registrational phase 2 trials initiating in 2021
- Advance innovations into first-in-human studies
- Strategic in-licensing to complement internal R&D
We Collaborate with Global Leaders in Our Industry

Collaborations for clinical stage programs

- **COVID-19 Vaccine**
  - 50:50 gross profit share
  - Companies keep full rights to own product

- **FixVac Melanoma**
  - 50:50 cost & profit share

- **iNeST**
  - 50:50 cost & profit share

- **Bispecific mABs**
  - 50:50 cost & profit share

- **Intra-tumoral mRNA**
  - cost & profit share

- **Seasonal Influenza**
  - royalties & milestones

Pre-clinical collaborations

- **Up to 10 Infectious Disease Indications**
  - worldwide opt-in right

- **HIV, Tuberculosis**
  - developed world rights

- **5 Rare Disease Indications**
  - 50:50 cost & profit share

150:50 cost & profit share refers to terms of Pfizer collaboration only (world-wide, ex-China)
Overview and business outlook

Deeper dive on our key programs

- COVID-19 vaccine program (project “Lightspeed”)
- mRNA vaccines – FixVac and iNeST
- Antibodies
- Cell Therapies – CARVac and NEO-STIM T cell therapy
- Small Molecule Immunomodulators
- RiboCytokines
## Oncology: 15 Product Candidates in 19 Ongoing Clinical Trials

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Platform</th>
<th>Product Candidate</th>
<th>Indication (Targets)</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Rights</th>
<th>Collaborator</th>
<th>Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRNA</td>
<td>FixVac (fixed combination of shared cancer antigens)</td>
<td>BNT111</td>
<td>advanced melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fully-owned</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA</td>
<td></td>
<td>BNT112</td>
<td>prostate cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fully-owned</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA</td>
<td></td>
<td>BNT113</td>
<td>HPV16+ head and neck cancer&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fully-owned</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA</td>
<td></td>
<td>BNT115</td>
<td>ovarian cancer&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fully-owned</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRNA</td>
<td>iNoST (patient specific cancer antigen therapy)</td>
<td>autogene cevumeran (BNT122)</td>
<td>1L melanoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sanofi (global profit/loss share)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RNA</td>
<td>Intratumoral Immunotherapy</td>
<td>SAR441000 (BNT131)</td>
<td>solid tumors (IL-12sc, IL-15sushi, GM-CSF, IFNα)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RNA</td>
<td>Ribocytokines (mRNA-encoded Cytokines)</td>
<td>BNT151</td>
<td>solid tumors (optimized IL-2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fully-owned</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RNA</td>
<td></td>
<td>BNT152 + BNT153</td>
<td>solid tumors (IL-7, IL-2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fully-owned</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antibodies</td>
<td>Next-Gen CP&lt;sup&gt;2&lt;/sup&gt; Immunomodulators</td>
<td>GEN1046 (BNT311)</td>
<td>solid tumors (PD-L1×4-1BB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genmab (global 50:50 profit/loss)</td>
<td>Data update in 2H 2021</td>
<td></td>
</tr>
<tr>
<td>Antibodies</td>
<td></td>
<td>GEN1042 (BNT312)</td>
<td>solid tumors (CD40×4-1BB)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Genmab (global 50:50 profit/loss)</td>
<td>Data update in 2H 2021</td>
<td></td>
</tr>
<tr>
<td>Antibodies</td>
<td>Targeted Cancer Antibodies</td>
<td>BNT321 (MVT-5873)</td>
<td>pancreatic cancer (sLea)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fully-owned</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMIM&lt;sup&gt;3&lt;/sup&gt;</td>
<td>Toll-Like Receptor Binding</td>
<td>BNT411</td>
<td>solid tumors (TLR7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fully-owned</td>
<td>Data update in 2H 2021</td>
<td></td>
</tr>
<tr>
<td>Cell Therapies</td>
<td>CAR-T Cells</td>
<td>BNT211</td>
<td>solid tumors (CLDN6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fully-owned</td>
<td>Data update in 2H 2021</td>
<td></td>
</tr>
<tr>
<td>Cell Therapies</td>
<td>Neoantigen-based T cell therapy</td>
<td>BNT221 (NEO-PTC-01)</td>
<td>solid tumors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>fully-owned</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>1</sup>BNT113 and BNT115 are currently being studied in investigator-initiated Phase 1 trials.  
<sup>2</sup>Checkpoint Inhibitor.  
<sup>3</sup>Small Molecule Immunomodulators.  
<sup>4</sup>FPD – First Patient Dosed
### Early-stage Oncology Pipeline: 2 Additional FIH\(^1\) Trials to Begin in 2021

<table>
<thead>
<tr>
<th>Drug class</th>
<th>Platform</th>
<th>Product Candidate</th>
<th>Indication (Targets)</th>
<th>Rights Collaborator</th>
<th>Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRNA</td>
<td>FixVac</td>
<td>BNT116</td>
<td>NSCLC</td>
<td>fully-owned</td>
<td></td>
</tr>
<tr>
<td></td>
<td>RiboMabs (mRNA-encoded antibodies)</td>
<td>BNT141</td>
<td>solid tumors</td>
<td>fully-owned</td>
<td>Phase 1 start in 2H 2021</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BNT142</td>
<td>solid tumors (CD3+CLDN6)</td>
<td>fully-owned</td>
<td>Phase 1 start in 2H 2021</td>
</tr>
<tr>
<td>Cell Therapies</td>
<td>CAR-T Cells</td>
<td>BNT212</td>
<td>pancreatic, other cancers (CLDN18.2)</td>
<td>fully-owned</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TCRs</td>
<td>to be selected</td>
<td>all tumors</td>
<td>fully-owned</td>
<td></td>
</tr>
</tbody>
</table>

\(^1\)first-in-human
# Broad Infectious Disease Pipeline

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Product Candidate</th>
<th>Indication (Targets)</th>
<th>Pre-clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Commercial</th>
<th>Rights / Collaborator</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRNA Vaccine</td>
<td>BNT162b2</td>
<td>COVID-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pfizer/Fosun</td>
</tr>
<tr>
<td></td>
<td>BNT161</td>
<td>Seasonal Influenza</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pfizer</td>
</tr>
<tr>
<td></td>
<td>Un-named program</td>
<td>Malaria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fully-owned</td>
</tr>
<tr>
<td></td>
<td>Un-named program</td>
<td>Tuberculosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BMGF*</td>
</tr>
<tr>
<td></td>
<td>Un-named program</td>
<td>HIV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>BMGF*</td>
</tr>
<tr>
<td></td>
<td>5 un-named programs</td>
<td>Undisclosed indications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fully-owned</td>
</tr>
<tr>
<td>Antibodies</td>
<td>Undisclosed program</td>
<td>COVID-19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fully-owned</td>
</tr>
</tbody>
</table>

*BMGF= Bill & Melinda Gates Foundation
Overview and business outlook

Pipeline

Deeper dive on our key programs

COVID-19 vaccine program (project “Lightspeed”)

mRNA vaccines – FixVac and iNeST

Antibodies

Cell Therapies – CARVac and NEO-STIM T cell therapy

Small Molecule Immunomodulators

RiboCytokines
Shipped >1.5 Billion Doses to >130 Countries & Territories Worldwide\textsuperscript{1}

A concerted and large-scale global effort

- **Full Marketing Approval received\textsuperscript{2}**
- **Conditional Marketing Authorization in the EU and Switzerland\textsuperscript{3}**
- **Approved Emergency Use Authorization / Temporary Use Approval**
- **Ongoing Phase 2 trial in China**

Submissions ongoing to pursue regulatory approvals in countries where emergency use authorizations or equivalents were initially granted are ongoing or planned.

\textsuperscript{1}As of September 22, 2021
\textsuperscript{2}Approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older; 2-dose series under Emergency Use Authorization for individuals 12-15 years old
\textsuperscript{3}The vaccine is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 12 years of age and older.
Project Lightspeed – a 10-month Journey to an Effective and Safe Vaccine

COVID-19 mRNA Vaccine Program Initiation
January 27, 2020

SARS-CoV-2 Genetic Sequence
Made Public January 12, 2020

Collaborations
Fosun Pharma: March 16, 2020
Pfizer: March 17, 2020

Phase 1 / 2 Trial
Germany Started April 23, 2020
U.S. Started May 4, 2020
4 vaccine candidates enter clinical testing

Initiated Pivotal Phase 2 / 3 Trial
Lead mRNA vaccine candidate chosen; up to 44,000 subjects
July 27, 2020

Phase 3 trial meets all primary efficacy endpoints; vaccine efficacy rate of 95%
November 18, 2020

Initiated Rolling Submissions
EMA: October 6, 2020
Canada: October 7, 2020
UK: October 9, 2020
Singapore
New Zealand
…and other countries

FDA Fast Track designation
July 13, 2020

Global roll-out has begun
Fully approved, approved for emergency use / temporary supply or Conditional Marketing Authorization in more than 80 countries worldwide including the U.S. and EU
December 2020
How mRNA Vaccines Work – Training the Immune System for a Real Infection

1. modRNA formulated in LNP enters cell
2. mRNA is released
3. Spike protein is made and processed
4. Virus Neutralizing Antibodies Bind Spike proteins and prevent virus infection of human cells

- CD4+ Helper T Cell
- CD8+ Cytotoxic T Cell
- Activates T and B cells
- Memory T and B cells Provide immune memory to ensure longer-term protection against SARS-CoV-2

- Eliminates virus infected cells; potentially increases length of protection
- B Cell
- Activates T and B cells

- Spike protein is made and processed
- Cap

- 5’UTR
- 3’UTR

- AAAAAA
mRNA is a Natural Solution for Vaccines Especially in a Pandemic

| Natural molecule with well-characterized bio-safety properties | Does not require addition of adjuvants or use of a vector for administration | Highly scalable production |
| High purity and animal free | Non-integrating into DNA and non-infectious unlike attenuated live virus and DNA based vaccines |

- Genetic information: SARS-CoV-2
- Vaccine mRNA
- mRNA LNP
- Clinical testing
- Phase 3 trials
- EUA / approval
- Vaccination
A Leading Provider Globally of COVID-19 Vaccines: ~2.2 Bn Doses Contracted for 2021*

<table>
<thead>
<tr>
<th>Selected Regions</th>
<th>2021 Orders</th>
<th>2022 and beyond</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU</td>
<td>660 m</td>
<td>900 m doses (plus option for additional 900 m)</td>
</tr>
<tr>
<td>U.S.</td>
<td>410 m</td>
<td>90 m</td>
</tr>
<tr>
<td>Other</td>
<td>~1.150 m</td>
<td>Canada, Israel and others</td>
</tr>
<tr>
<td>TOTAL</td>
<td>~2.2 bn</td>
<td>&gt; 1 bn (excl. options)</td>
</tr>
</tbody>
</table>

Ongoing discussions for additional doses in 2021/2022 and beyond

2 bn doses pledged over the next 18 months to ensure global equitable vaccine access

Targeting up to 3.0 bn doses capacity in 2021 and up to 4.0 bn in 2022*

Marburg facility: Targeting 1 bn dose annual run-rate capacity once fully operational

---

1As of July 21, 2021.
2*This assumes continuous process improvements and expansion at our current facilities and contingent upon adding more suppliers and contract manufacturers.
Significant Progress Across Six Key Levers to Expand COVID-19 Vaccine Reach

**Increased Manufacturing Capacity**
- Continued efforts to establish multi-continent manufacturing capabilities to support global vaccine needs
- South Africa and Latin America collaborations to expand BNT/Pfizer manufacturing network

**Label Expansion to Additional Populations**
- Expansion of authorizations for adolescents 12 years of age and older in U.S., EU and other countries
- Submitted initial clinical data on children 5 to <12 years of age to FDA; EMA submission planned
- Ongoing trial in children 2 to 11 years and 6 months to 2 years of age: data expected Q4 2021
- Global Phase 2/3 trial in healthy pregnant women

**Regulatory Advancement Across All Geographies**
- First COVID-19 vaccine to receive full FDA approval
- Converting existing emergency use authorizations into regulatory approvals globally
- Regulatory submission for BLA in China underway

**Optimize Formulations to Further Simplify Access Worldwide**
- Storage at 2-8 °C for 31 days approved by multiple regulators, including EMA and FDA
- Phase 3 trial for ready-to-use and lyophilized formulations

**Addressing Waning Immune Reponses**
- Booster dose granted EUA by FDA for 65+ years of age and certain high-risk groups 18 to 64 years of age
- Initial, preliminary booster data: ~6 months after dose 2 of BNT162b2 show overall consistent tolerability profile while eliciting SARS-CoV-2 neutralization titers against wild type, Beta and Delta variant

**Addressing SARS-CoV-2 Variants**
- Expanded trials for third booster dose of BNT162b2 and multiple variant-specific approaches in both vaccine-naive and previously vaccinated individuals 6-12 months post dose 2

---

EMA, European Medicines Agency; FDA, U.S. Food and Drug Administration;
1Approved as a 2-dose series for prevention of COVID-19 in individuals 16 years of age and older; 2-dose series under Emergency Use Authorization for individuals 12-15 years old
Strong Clinical Results: Vaccine Efficacy Remains High up to 6 Months Following 2\textsuperscript{nd} Dose\textsuperscript{1,2}

- 95% effective against symptomatic COVID-19\textsuperscript{1}
- Up to 6 months after dose 2\textsuperscript{2}:
  - 91.2% effective against symptomatic disease
  - 95.7% effective against severe disease
- Well tolerated safety profile
- High titers of neutralizing antibodies
- Robust and poly-epitopic CD8+ and Th1 CD4+ T-cell responses\textsuperscript{3}

\textsuperscript{1}Polack FP, et al. NEJM 2020, 383:2603-2615
Data Demonstrates Protection Against Circulating SARS-CoV-2 Variants Including Delta Variant

Neutralizing antibody titers

Reduced, yet preserved in vitro neutralizing activity of immune sera against several variants of concern, including: Alpha, Gamma, Beta, Eta, Delta

Poly-specific T cell responses

Vaccinated individuals generate a T cell response targeting epitopes conserved across a number of variants, including the Delta variant

Real world data

Observed effectiveness against variants of concern including Delta variant (95%CI)

<table>
<thead>
<tr>
<th>Real-World Study</th>
<th>Timepoint</th>
<th>Infection</th>
<th>Symptomatic</th>
<th>Hospitalization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public Health England, NEJM</td>
<td>≥14d post 2d – up to 2-3m</td>
<td>88 (78-93)</td>
<td>--</td>
<td>96 (86-99)</td>
</tr>
<tr>
<td>July 2021; preprint July 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public Health Ontario, Canada,</td>
<td>≥7d post 2d – up to 1-2m</td>
<td>--</td>
<td>87 (64-95)</td>
<td>100</td>
</tr>
<tr>
<td>preprint July 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public Health Scotland, Lancet</td>
<td>≥14d post 2d – up to 2-3m</td>
<td>79 (75-82)</td>
<td>--</td>
<td>--</td>
</tr>
<tr>
<td>June 2021</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Israel, MoH</td>
<td>≥7d post 2d – up to 6m</td>
<td>39 (9-59)</td>
<td>41 (9-61)</td>
<td>88 (79-93)</td>
</tr>
</tbody>
</table>

1. Liu J et al Nature 2021
2. Xie X et al Nature Med 2021
3. Sahin U et al Nature 2021
4. Bernal et al. NEJM 2021
BNT162b2 Booster Dose Results in a Broad, Robust Neutralisation Response

Booster dose could prolong protection and further increase breadth of protection against SARS-CoV-2 variants

- 3rd dose strongly boosts neutralizing titers both in younger and older adults against
  - Wild type > 5-8-fold
  - Delta variant > 5-11-fold
  - Beta variant > 15-21-fold

when comparing month 1 data after dose 2 or dose 3

- Wild type and Beta variant titers continue to increase comparing day 7/month 1 data after dose 2 versus dose 3

- Overall consistent tolerability profile

Data being prepared for submission to regulatory authorities globally.
## Preemptive Strategy to Address SARS-CoV-2 Variants

- Establishing development, manufacturing and regulatory pathway for variant-specific prototype approach

### Prototype Approach substantiated by broad clinical data

<table>
<thead>
<tr>
<th>Study Start</th>
<th>BNT162b2: 3&lt;sup&gt;rd&lt;/sup&gt; dose Safety &amp; immunogenicity trial</th>
<th>BNT162b2: 3&lt;sup&gt;rd&lt;/sup&gt; dose Safety &amp; efficacy trial</th>
<th>Beta: 3&lt;sup&gt;rd&lt;/sup&gt; dose or naïve Safety &amp; immunogenicity trial</th>
<th>Multivalent Delta + Alpha or Delta or Alpha: 3&lt;sup&gt;rd&lt;/sup&gt; dose or naïve: Safety &amp; immunogenicity trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 2021</td>
<td>March 2021</td>
<td>March 2021</td>
<td>August 2021</td>
<td></td>
</tr>
<tr>
<td>Nb of participants (trial phase)</td>
<td>• N=23 (ph 1) &lt;br&gt; • N=~300 (ph 2/3)</td>
<td>• N=~10,000 (ph 3)</td>
<td>• N=~300 (ph 3) &lt;br&gt; • N=~300 (naïve)</td>
<td>• N=~600 &lt;br&gt; • N=~300 (naïve)</td>
</tr>
<tr>
<td>Boosting post dose 2</td>
<td>6-12 months</td>
<td>6 months</td>
<td>5-7 months</td>
<td>&gt;6 months</td>
</tr>
<tr>
<td>Data expected</td>
<td>First data published</td>
<td>Q4 2021</td>
<td>Q3 2021</td>
<td>Q4 2021</td>
</tr>
</tbody>
</table>

**Study Start**
- March 2021
- July 2021
- March 2021
- August 2021

**Nb of participants (trial phase)**
- N=23 (ph 1)
- N=300 (ph 2/3)
- N=10,000 (ph 3)
- N=300 (ph 3)
- N=300 (naïve)
- N=600
- N=300 (naïve)

**Boosting post dose 2**
- 6-12 months
- 6 months
- 5-7 months
- >6 months

**Data expected**
- First data published
- Q4 2021
- Q3 2021
- Q4 2021
Flexible Manufacturing Allows Rapid Adaptation to Variants

1. DNA template production ~1-2 Days
2. mRNA production ~1-2 Days
3. Drug substance purification and concentration ~1-2 Days
4. LNP formulation ~3-4 Days
5. Sterile filtration & filling ~1-2 Days

Quality control and release 4-5 weeks
Global Consortium to Address Pandemic - BNT162 Global Collaborations

- Co-development and co-commercialization worldwide (ex China) if approved
- Combined upfront payment and equity investment of $185 million to BioNTech received in April
- Capital expenditures to be funded by each party independently
- Companies to share development expenses and gross profits on a 50:50 basis
- BioNTech eligible to receive further development & sales milestones up to $563 million

- Co-development with Fosun Pharma to hold exclusive marketing rights in China if approved
- Combined upfront payment and equity investment of $51 million to BioNTech received in April
- Fosun Pharma to fund development expenses in China
- BioNTech and Fosun to share gross profits on the sale of the vaccine in China
- BioNTech eligible to receive further China development & sales milestones up to $84 million
Overview and business outlook

Pipeline

Deeper dive on our key programs

COVID-19 vaccine program (project “Lightspeed”)

mRNA vaccines – FixVac and iNeST

Antibodies

Cell Therapies – CARVac and NEO-STIM T cell therapy

Small Molecule Immunomodulators

RiboCytokines
Our mRNA Vaccine Platforms: FixVac and iNeST

- **FixVac**
  - Off-the-shelf mRNA immunotherapy
  - Targeting a fixed combination of shared antigens
    - Non-mutated shared antigens shared across patients
    - Applicable for almost all types of tumor antigens

- **iNeST**
  - Fully individualized mRNA immunotherapy
  - Targeting 20 neo-antigens unique to each patient
    - Vast majority of neo-antigens are unique to individual patients
    - Applicable across solid tumor types

**Proprietary RNA-LPX formulation for systemic dendritic cell targeting**

- Strong immunogenicity observed *in vivo* via TLR7-driven adjuvant effect
- Potent induction of strong *ex vivo* CD4+ and CD8+ T cell responses
Our RNA-LPX Vaccine Approach

Strong vaccine-induced *ex vivo* CD8+ T cell responses\(^1\) across different cancer types

- **NY-ESO-1**
  - Melanoma
  - BNT111, Lipo-MERIT trial
  - 10.1%

- **MAGE-A3**
  - Melanoma
  - BNT111, Lipo-MERIT trial
  - 2.1%

- **HPV16-E7**
  - Head Neck Cancer
  - BNT113, HARE40 trial
  - 5.0%

- **Mutant Neoantigen**
  - TNBC
  - BNT114, TNBC MERIT trial
  - 10.3%

\(^1\) T cell responses analyzed by *ex vivo* multimer staining analysis in blood
FixVac: Leveraging Shared Antigens to Break Immune Tolerance

Off-the Shelf Concept: Scalable for multiple indications

Targeting antigen presenting cells to stimulate antigen-specific T cell responses

- Strong immunogenicity observed in vivo via TLR-driven adjuvant effect
- Potent induction of strong ex vivo CD4+ and CD8+ T cell responses

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Indication (Targets)</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>BNT111</td>
<td>Advanced melanoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNT112</td>
<td>Prostate cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNT113</td>
<td>HPV16+ head and neck cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNT116</td>
<td>NSCLC</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

RNA-LPX, RNA-Lipoplex; IV, intravenous; TLR7, Toll-like receptor; NY-ESO-1, New York esophageal squamous cell carcinoma-1; MAGE-A3, melanoma-associated antigen 3; HPV-E7, Human papillomavirus (type 16) E7 oncoprotein; HPV, Human papillomavirus; NSCLC, Non small cell lung cancer; HLA, human leukocyte antigen; CD, cluster of differentiation

BNT111 FixVac Melanoma: Started Randomized Phase 2 Trial

- Ongoing Phase 1 trial in Advanced Melanoma published in Nature
  - Phase 1 trial data in CPI-experienced patients in monotherapy and in combination with anti-PD1 previously reported in July 2020 and published in Nature
  - All patients showed tumor associated antigen (TAA) specific T cell responses with In vitro stimulation, and > 75% of patients showed immune responses against ≥ 1 TAA on an ex vivo basis
    - T cells responses ramped up over 4-8 weeks and increased or remained stable up to over one year with monthly maintenance therapy
  - **Reported durable clinical responses in monotherapy and in combination with anti-PD1 accompanied by high magnitude CD4+ and CD8+ response**

- Regeneron strategic collaboration and ongoing Phase 2 trial
  - Strategic collaboration to jointly conduct randomized Phase 2 trial with BNT111 and Libtayo® (cemiplimab anti-PD-1 therapy)
  - Targeting patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV cutaneous melanoma
  - Companies to share development costs equally and keep full commercial rights to own programs
  - First patient was dosed in June 2021
BNT111: Off-the Shelf Therapeutic Vaccine for Melanoma

Potential to Improve Outcomes in Combination with Anti-PD1 by Rescuing from T Cell Exhaustion

BNT111 encodes 4 tumor-associated antigens covering >90% of cutaneous melanoma patients

- NY-ESO-1
- Tyrosinase
- MAGE-A3
- TPTE

Phase 1 trial data published in Nature:
- Tolerable safety as monotherapy and in combination with anti-PD1
- Durable objective responses in CPI-experienced patients with unresectable melanoma
  - ORR: BNT111 monotherapy: 3/25 PR; 8/25 SD
  - ORR: 35% in combination with anti-PD1: 6/17 PR; 2/17 SD
- Clinical responses accompanied by strong CD4+ and CD8+ T cell immunity

NY-ESO-1, New York esophageal squamous cell carcinoma-1; MAGE-A3, melanoma-associated antigen 3; TPTE, transmembrane phosphatase with tensin homology; AAAA, Poly-A tail; PD1, Programmed cell death protein 1; CPI, check point inhibitor; R/R, refractory/resistant; PR, partial response; SD, stable disease; ORR, Overall Response Rate; CD, Cluster of Differentiation;

BNT111: Treatment Options Needed to Address CPI Failure in Advanced Melanoma Patients

Melanoma Remains the Deadliest Skin Cancer

### Incidence
- **↑ 50%**
  - Annual cases have increased by nearly 50% to over 287,000

### Deaths
- **↑ 20%**
  - WHO predicts by 2025, number of deaths will increase by 20%

### CPI R/R patients
- **~ 55%**
  - Patients refractory to or relapse on CPI treatment, leaving them with limited treatment options

**Significant Opportunity to Improve on Standard of Care**

- 5-year survival for metastatic melanoma still only 29.8%
- Frontline immunotherapy with CPI induces durable responses in max. 45-50% of patients but with relatively short PFS
- CPI resistant/ refractory patients that fail to respond to CPI or relapse after CPI have an especially poor prognosis with survival as short as 6 months depending on risk factors
- Advanced CPI R/R melanoma is a high medical need population with highly unfavorable prognosis

---

WHO, World Health Organization; CPI, check point inhibitor; R/R, refractory/resistant; mPFS, median progression free survival; ORR, Overall Response Rate; DoR, Duration of Response

4. Larkin J. et al. NEJM 2019;381(16):1535-1546
BNT111: Global Phase 2 Clinical Trial in Anti-PD1 R/R Melanoma Patients

Open-label, randomized Phase 2 trial
- BNT111 and cemiplimab in combination or as single agents
- Collaboration with Regeneron

Success Measures for BNT111 Trial
ORR 30%

Primary Endpoints
- Arm 1: ORR by RECIST 1.1

Secondary Endpoints
- ORR (key secondary endpoint arms 2, 3)
  DOR, DCR, TTR, PFS by RECIST 1.1
- OS, safety, tolerability, PRO

Patients with anti-PD1-R/R, unresectable Stage III or IV melanoma

BNT111-01

BNT111 + cemiplimab ≤ 24 months

BNT111 ≤ 24 months

Cemiplimab ≤ 24 months

Addition of cemiplimab upon disease progression

Addition of BNT111 upon disease progression

OS Follow-up every 3 months for ≤ 48 months from first dose

PD1, Programmed cell death protein 1; R/R, refractory/relapsed; ORR, overall response rate; DoR, Duration of Response; DCR, disease control rate; TTR, time to response; PFS, progression free survival; OS, overall survival; PRO, patient reported outcomes
https://clinicaltrials.gov/ct2/show/record/NCT04526899

39
BNT113: Potential to Increase Response Rate and DoR to CPI by Stimulating Immune Response Against HPV16 Proteins

BNT113 encodes HPV16 oncoproteins E6 & E7

- E6 and E7 proven to be well-suited for immunotherapy intervention
- Exclusively expressed in pre-malignant and malignant tissue
- Maintain the transformed state of infected malignant cells
- Demonstrated immunogenicity
- Not affected by central tolerance mechanisms

BNT113 combination with anti-PD1: Potential for synergistic anti-tumor effect delaying escalation to toxic chemo

HPV, human papilloma virus; DoR, Duration of Response; CPI, check point inhibitor
BNT113: Potent Antigen-Specific T Cell Responses in Phase 1 Trial\textsuperscript{1,2}

- CD4\textsuperscript{+} and CD8\textsuperscript{+} T cell responses
- Responses detectable ex vivo, implying high numbers of T cells
- Responses against multiple E6 or E7 epitopes

\textbf{A}  

\begin{center}
\begin{tabular}{|c|c|c|c|c|c|c|c|}
\hline
\textbf{Arm 1A, adjuvant} & \textbf{Antigen} & \textbf{Cohort 1} & \textbf{Cohort 2} & \textbf{Number of patients} & \textbf{Type of response to E6} \\
& & \textbf{TD 29 µg} & \textbf{TD 78.2 µg} & & \\
\hline
\textbf{Arm 1A} & \textbf{E6} & \textbf{CD8} & \textbf{CD8} & \textbf{CD4} & \textbf{CD8} & \textbf{CD4/CD8} & \textbf{CD8} & \textbf{Bulk} & \textbf{CD8} & \textbf{NR} & \textbf{22\%} & \textbf{33\%} & \textbf{45\%} \\
\hline
\textbf{E7} & \textbf{NR} & \textbf{NR} & \textbf{NR} & \textbf{NR} & \textbf{NR} & \textbf{CD8} & \textbf{NR} & \textbf{NE} & \textbf{NR} & \textbf{NR} \\
\hline
\end{tabular}
\end{center}

\textbf{B}  

\begin{center}
\begin{tabular}{|c|c|c|}
\hline
\textbf{Pre vaccination} & \textbf{Post vaccination} & \\
\hline
\textbf{CD8 response to vaccine targets} & \\
\textbf{Pepmix} & \textbf{E6} & \\
\textbf{Pepmix} & \textbf{E7} & \\
\textbf{PBMCs only} & \\
\textbf{Anti-CD3} & \\
\hline
\textbf{CD4 response to vaccine targets} & \\
\textbf{Pepmix} & \textbf{E6} & \\
\textbf{PBMCs only} & \\
\textbf{Anti-CD3} & \\
\hline
\end{tabular}
\end{center}

TD, total dose; CD, Cluster of Differentiation; NE, Not Evaluated; NR, Not Reported; PBMC, peripheral blood mononuclear cells

\textsuperscript{1}HARE-40 trial  
\textsuperscript{2}Presented at CIMT 2019; BNT113 is currently being studied in an investigator-initiated Phase 1 trial.  
\textsuperscript{3}ELISPOT (Enzyme Linked Immuno Spot Assay) data of selected patients. Data were generated using IFN-γ ELISPOT directly ex-vivo with overlapping peptides covering the whole length of vaccine antigens (PepMix).
BNT113: Unmet Medical Need for HPV-Associated HNSCC

HPV+ Cancer is a Growing Global Public Health Concern

- Several types: HNSCC, Cervical, Anal, Vulvar, Vaginal, Penile
- HNSCC is the sixth most common cancer worldwide, with 890,000 new cases and 450,000 deaths in 2018
- Oropharyngeal is most common HNSCC, accounting for 70% of cases, and 80-90% are HPV16+³

Limited treatment options for patients not responding to or relapse on CPI¹

- HPV16+ HNSCC typically occur in younger people and is not associated with tobacco or alcohol use
- >60% of patients diagnosed with late-stage HNSCC
- Current treatment options carry significant treatment burden or only work for some patients⁴:
  - Chemotherapy, surgery, radiation
  - CPI

Current SOC for recurrent/metastatic HNSCC

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ORR</th>
<th>mOS (months)</th>
<th>mPFS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pembrolizumab⁵</td>
<td>17%</td>
<td>13.6</td>
<td>8.0</td>
</tr>
<tr>
<td>nivolumab⁶</td>
<td>13.3%</td>
<td>7.7</td>
<td>2.0</td>
</tr>
<tr>
<td>chemotherapy⁴</td>
<td>5.8%</td>
<td>5.1</td>
<td>2.3</td>
</tr>
</tbody>
</table>

BNT113: First Patient Dosed in Potentially Registrational Phase 2 Trial in HPV16+ and PD-L1+ HNSCC

Open-label, controlled, Phase 2 study
- BNT113 in combination with pembrolizumab as frontline treatment for metastatic HPV16+ and PD-L1+ HNSCC
- HPV 16 companion diagnostic is being co-developed and will be clinically validated alongside the trial

Primary Endpoints
- Part A: Emergence of TEAEs
- Part B: OS, ORR

Secondary Endpoints
- PFS, DCR, DOR
- Safety
- Patient reported outcomes

Success Measures for BNT113 Trial
- mOS: 18 months (HR=0.667)
- ORR: 40%

HPV, human papilloma virus; PD-L1, programmed death-ligand 1; CPS, Combined positive score; HNSCC, head and neck squamous cell carcinoma; SRC, safety review committee; TEAEs, treatment emergent adverse events; OS, overall survival; mOS, median overall survival; ORR, overall response rate; HR, hazard ratio; DOR, duration of response; DCR, disease control rate; PFS, progression free survival

https://www.clinicaltrials.gov/ct2/show/NCT04534205
iNeST\textsuperscript{1}: Tailored Treatment to Exploit Individual Targets

- Fully customized to the individual Patient
- Targeting 20 neo-antigens per patient

\begin{itemize}
  \item Ongoing Phase 2 trial in adjuvant colorectal cancer
  \item Phase 1 trial data: 8 of 8 stage III/IV melanoma patients with stable disease cancer free for \textbf{up to 60 months} (BNT121)\textsuperscript{1}
  \item Ongoing Phase 2 trial in 1L melanoma
  \item Single agent activity in melanoma\textsuperscript{2} and gastric\textsuperscript{3} cancer
  \item Encouraging efficacy signal validates iNeST potential in early settings
\end{itemize}

\textsuperscript{1} iNeST is partnered with Genentech/Roche in a 50:50 cost/profit split  
\textsuperscript{2} Sahin et. al. Nature 20  
\textsuperscript{3} AACR 2020
iNeST: Recent Update from BNT122 Reported at AACR

Phase 1a dose escalation: Monotherapy in locally advanced or metastatic solid tumors

- 31 patients enrolled, cohorts with doses ranging from 25-100ug
  - Most common tumor types were HR+/HER2+ breast, prostate, and ovarian cancer
  - Median of 5 lines of prior therapies (range 1-17)
  - Most patients enrolled had low level of PD-L1 expression in tumor

- Neoantigen-specific T cell responses observed in peripheral blood in 86% of patients, significant T cell expansion and both naïve and memory activated phenotype
- Of 26 patients with at least one tumor assessment,
  - 1 patient with gastric cancer and metastatic liver lesions had confirmed CR (ongoing for 10 months)
  - 12 patients had SD

Phase 1b combination with atezolizumab demonstrated clinical activity in heavily pre-treated patients

- 132 patients enrolled, cohorts with doses ranging from 15-50μg
  - Heavily pre-treated patient population
    - Both CPI experienced and inexperienced
    - Most patients with low PD-1
  - Clinical responses associated with T cell response, correlating immune profiling of patients’ T cells to cancer-specific response
- Of 108 patients with at least one tumor assessment
  - 1 patient had CR as best response (0.9%),
  - 8 patients had PR (7.4%), and
  - 53 patients had SD (49.1%)

- Demonstrates ability to elicit significant T cell responses of both effector and memory phenotype as monotherapy and in combination
- Treatment-related adverse events were primarily transient systemic reactions, manifesting as low grade CRS, IRR or flu-like symptoms
- Early evidence of clinical activity in highly refractory patient population

Note: Patients in both cohorts received personalized product manufactured on per patient basis with up to 20 patient-specific neoantigens, in both cohorts majority of AEs were Grad 1 or Grade 2
iNeST: Recent Update from BNT122 Reported at AACR (Cont’d)

BNT122 induces CD8+ T cells in CPI-sensitive and CPI-insensitive tumor types

Patient With Prostate Cancer Treated With RO7198457 (38 µg)

- Baseline: 0.03%
- C2D1: 1.95%
- C3D1: 2.49%
- C4D1: 4.7%

Phenotype of MHC Multimer–Positive Cells

- Effector Memory Phenotype
- PD-1+ Cells

BNT122 induces CD8+ T cell infiltrates in tumors

RO7198457-specific TCRs are present only in post-treatment tumor.

Frequency of TCRs (log_10) in Baseline Tumor

Frequency of TCRs (log_10) in Post-Treatment Tumor

PD-1+ CD8 T cells 99.6%
BNT122 iNeST Randomized Phase 2 Trials Ongoing and Planned

**First-line advanced melanoma**

- A Phase 2, open-label, multicenter randomized trial of the efficacy and safety of BNT122 in combination with pembrolizumab vs. pembrolizumab in patients with previously untreated Advanced Melanoma

**Rationale**

- Evaluate added benefit of 1L BNT122 in an advanced CPI-sensitive tumor (PFS, ORR)
- Success may unlock 1L use of iNeST in CPI-sensitive advanced cancers for combination therapy

**Status**

- Currently enrolling

**Adjuvant colorectal cancer**

- A Phase 2, open-label, multicenter randomized trial to compare the efficacy of BNT122 versus watchful waiting in patients with ctDNA positive, surgically resected Stage 2/3 rectal cancer, or Stage 2 high risk/stage 3 colon cancer

**Rationale**

- Evaluate added benefit of BNT122 in a micrometastatic CPI-insensitive tumor (RFS)
- Success may unlock adjuvant use of iNeST for CPI-insensitive ctDNA+ cancer types

**Status**

- Currently enrolling
BNT122: Randomized Phase 2 Trial in Adjuvant Colorectal Cancer

Patients with resected stage II high-risk / stage III CRC post surgery

**Screening 1:** ctDNA status

**Screening 2:** neoantigen selection for vaccine manufacture

**Screening 3:** final eligibility

Patients in biomarker cohort skip screening 1

**Phase 2, open-label, multicenter randomized trial**
- BNT122 versus watchful waiting in ctDNA positive patients with surgically resected Stage II (high risk) / stage III colorectal cancer

**Primary Endpoints**
- DFS

**Secondary Endpoints**
- RFS, TTR, TTF, OS
- Change in ctDNA status

**Adjuvant SOC chemotherapy:**
12 - 24 weeks

**Treatment Arm: BNT122**
15 doses (6x q1w, 2x q2w, 7x q6w)

**Observational Arm**
watchful waiting

1:1 R n = 166

**Biomarker Cohort: BNT122**
irrespective of ctDNA status
n = 15

**iNeST Manufacturing**
≤ 20 neoepitopes

**Exploratory Cohort: BNT122**
recurrent disease at screening 3
n ≤ 20

CRC, colorectal cancer; ctDNA, circulating tumor DNA; SOC, standard of care; q1w, once weekly; q2w, every two weeks; q6w, every six weeks; DFS, disease-free survival; RFS, relapse-free survival; TTR, time to response; TTF, time to treatment failure; OS, overall survival; https://www.clinicaltrials.gov/ct2/show/NCT04486378; BNT122/iNeST is partnered with Genentech/Roche.
Digitalization and Automation for Neo-antigen Vaccine Manufacturing

- 2 mRNA GMP production facilities: Idar-Oberstein (GMP since 2011) and Mainz (GMP since 2018)
- Construction and GMP licensure of new Mainz facility for iNeST expected in 2022/2023
- Partnered with Siemens to develop automated production processes
## Overview and business outlook

- Pipeline

## Deeper dive on our key programs

- **COVID-19 vaccine program (project “Lightspeed”)**
- mRNA vaccines – FixVac and iNeST
- **Antibodies**
- Cell Therapies – CARVac and NEO-STIM T cell therapy
- Small Molecule Immunomodulators
- RiboCytokines
BNT311: Next-generation Bispecific Antibody PD-L1x4-1BB

- **Next-generation immunotherapy** designed to enhance T cell and NK cell function through conditional 4-1BB co-stimulation while simultaneously blocking PD-L1 axis
- Bispecific antibody is 50:50 profit/loss share partnered with Genmab

---

**Interim results of ongoing Phase 1/2a trial presented at SITC 2020**

Phase 1/2a dose escalation and expansion trial in heavily pretreated patients with advanced solid tumors to evaluate safety and initial anti-tumor activity

- Dose escalation (n=61) data demonstrated **manageable safety profile** and **preliminary clinical activity** across advanced solid tumors
- Expansion cohort (n=24) in NSCLC patients demonstrated **encouraging preliminary responses**
BNT311: Safety Trial in Patients with Malignant Solid Tumors (NCT03917381)

Phase 1
Dose Escalation
N = 61

Metastatic or unresectable solid tumors in patients who are not candidates for standard therapy

BNT311/GEN1046: intravenous flat dose every 3 weeks until disease progression or unacceptable toxicity

Study Endpoints
- Safety and tolerability
- PK/PD
- Anti-tumor activity
- Biomarkers

Phase 2a
Dose Expansion
N = Up to 40 per cohort

8 expansion cohorts are currently recruiting

- EC1: NSCLC ≤ 2-4L p. CPI
- EC2: NSCLC ≤ 2-4L CPI n.
- EC3: Urothelial Ca ≤ 2-4L p. CPI
- EC4: Endometrial Ca ≤ 2-4L CPI n.
- EC5: TNBC ≤ 2-4L CPI n./ p. CPI
- EC6: SCCHN ≤ 2-4L CPI n./ p. CPI
- EC7: Cervical Ca ≤ 2-4L CPI n.
- EC9: Basket BNT311 + Docetaxel
BNT311: Interim Results of Ongoing Phase 1/2a Trial
Manageable Safety Profile and Initial Clinical Activity in FIH Trial

**Safety**
- Most treatment-related AEs mild to moderate
- No treatment-related bilirubin increases or Grade-4 transaminase elevations
  - Grade-3 elevations resolved
  - 6 patients had DLTs
  - MTD not reached

**Dose escalation**
- Clinical benefit **across different dose levels and solid tumor types**
- Disease control in **65.6% of patients**
- 4 partial responses:
  - TNBC (1), ovarian cancer (1), CPI* pre-treated NSCLC (2)
- Modulation of **circulating CD8+ T cells** and serum levels of interferon gamma and IP10 observed
  - Maximal induction 8-15 days after treatment

**Dose expansion**
- Encouraging preliminary efficacy in 12 PD-L1 relapsed/refractory NSCLC patients
  - 2 confirmed partial responses
  - 1 unconfirmed partial response
  - 4 patients demonstrated stable disease
- Enrollment ongoing in 6 additional cohorts

*CPI – checkpoint inhibitor; SITC 2020, Garralda et al., Poster #412*
The most common treatment-related adverse events were transaminase elevations, hypothyroidism and fatigue.

Treatment-related transaminase elevations occurred in 26.2% of patients (9.8% of patients had grade 3 transaminase elevations).

There were no patients with Grade 4 transaminase, or treatment-related bilirubin increases.

MTD has not been reached.
BNT311: Interim Results of Ongoing Phase 1/2a- Anti-tumor Activity Dose Escalation

Disease control achieved in 65.6% of patients; four patients with PR
Includes 4 early partial responses in TNBC (1), ovarian cancer (1), and ICI-pre treated NSCLC (2) patients

Data cut-off: September 29, 2020. Post-baseline scans were not conducted for five patients.
Minimum duration of response (5 weeks) per RECIST v1.1 not reached.
PR was not confirmed on a subsequent scan.
NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PR, partial response; SD, stable disease; SoD, sum of diameters; uPR, unconfirmed partial response.
BNT311: Interim Results of Ongoing Phase 1/2a – Anti-tumor Activity in CPI Recurrent/Refractory NSCLC Expansion

As of October 12, 2020, 24 patients were enrolled in expansion cohort 1, which includes patients with NSCLC with progression on or after ICI therapy

• 12 patients had post-baseline scans; 6 patients were still on treatment with BNT311/GEN1046, 6 patients discontinued
• Preliminary efficacy in 12 patients who could be objectively assessed showed two patients who achieved confirmed PR, one with unconfirmed PR, and four patients with SD

*Denotes patients with ongoing treatment.
aPR was not confirmed by a subsequent scan.
Includes all patients who had at least one post-baseline tumor assessment (schedule is every 6 weeks), and thus could be assessed for clinical benefit; 6 of 12 patients are still on treatment.
BOR, best overall response; ICI, immune checkpoint inhibitor; NA, not available, NE, non-evaluable; NSCLC, non-small cell lung cancer; PD, progressive disease; PD-(L)1, programmed death (ligand) 1; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SoD, sum of diameters; TPS, tumor proportion score; uPR, unconfirmed partial response.
Agenda

Overview and business outlook

Deeper dive on our key programs

- COVID-19 vaccine program (project “Lightspeed”)
- mRNA vaccines – FixVac and iNeST
- Antibodies
- Cell Therapies – CARVac and NEO-STIM T cell therapy
- Small Molecule Immunomodulators
- RiboCytokines
Proprietary Cell Therapy Pipeline and Capabilities

- Two cell therapy manufacturing facilities (Idar-Oberstein, Germany and Gaithersburg, U.S.)

<table>
<thead>
<tr>
<th>CARVac</th>
<th>NEOSTIM</th>
<th>Personalized TCR-T cell therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAR-T cell amplifying mRNA therapy for solid tumors</td>
<td>individualized neoantigen-T cell therapy</td>
<td>Ex-vivo engineered neoantigen specific TCR-T cell therapy further strengthened by an acquisition from Kite</td>
</tr>
<tr>
<td>Next generation CAR-T targeting CLDN6 with CARVac</td>
<td>Patient’s PBMCs used to induce and expand multiple CD4$^+$ and CD8$^+$ neoantigen T cell populations ex-vivo</td>
<td></td>
</tr>
</tbody>
</table>
BNT211: Repeated CARVac Dosing Enables Tunable Expansion of CAR-T Cells

**CAR-T cell Amplifying RNA Vaccine (CARVac)** drives in vivo expansion and efficacy of CAR-T against solid tumors

- CARVac is based on RNA-LPX that selectively targets secondary lymphoid organs
- I.V. administration of CLDN6 RNA-LPX results in expression of CAR antigen on APCs
- Repetitive administration of CARVac results in increased frequency, persistence and activity of CAR-T cells with a memory phenotype
- Combination of sub-therapeutic CAR-T dose and CARVac demonstrated eradication of advanced tumors in mice

---

**CARVac production**

CAR-targeted antigen encoding mRNA

Liposomes

RNA-LPX

---

**CARVac based CAR-T expansion**

CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor engineered T cells; RNA-LPX, RNA-lipoplex; APCs, antigen presenting cells

BNT211: CLDN6-CAR Demonstrates Potent and Robust Target Recognition

- Directed against new carcino-embryonic antigen CLDN6
- 2nd generation CAR functionalized with antibody-derived CLDN6-binding domain (αCLDN6-scFv)
- Binding domain mediates exclusive specificity and high sensitivity for CLDN6
- Costimulatory domain (4-1BB) mediates prolonged survival and repetitive killing ability
- CLDN6-CAR showed strong recognition and lysis of CLDN6-positive target cells in preclinical studies

CLDN6 not present in healthy tissues

CLDN6 expressed in multiple cancers

Ovarian  Testicular  Lung

BNT211 CAR Structure

- αCLDN6 scFv
- CD8 hinge
- 4-1BB
- CD3ζ

CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor engineered T cells; scFv, single chain variable fragment

BNT211: Next Generation CAR-T Therapy in Solid Tumors

An open-label Phase 1/2a study of BNT211 in patients with advanced solid tumors

- Evaluation of safety and tolerability
- Ongoing Phase 1/2a study
- Monotherapy dose level 1 completed (3 patients)
- Data update in 2H 2021

CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor engineered T cells; RP2D, recommended Phase 2 dose; NOS, not otherwise specified


Part 1
CLDN6 CAR-T

dose escalation

Part 2
CLDN6 CAR-T + CLDN6 CARVac

dose escalation

Part 3 Expansion Cohorts
- Ovarian Cancer
- Testicular Cancer
- Endometrial Cancer
- Lung Cancer
- Gastric Cancer
- Tumors NOS
BNT211: CAR-T Engraftment and Stable Disease in First 2 Patients

<table>
<thead>
<tr>
<th>Patient #</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, gender</td>
<td>68 y, female</td>
<td>25 y, male</td>
<td>33 y, male</td>
</tr>
<tr>
<td>Tumor entity</td>
<td>Ovarian CA</td>
<td>Sarcoma</td>
<td>Testicular CA</td>
</tr>
<tr>
<td>CLDN6 II/III+</td>
<td>60%</td>
<td>80%</td>
<td>60%</td>
</tr>
<tr>
<td>Stage</td>
<td>FIGO IIIc</td>
<td>unknown</td>
<td>IIIc</td>
</tr>
<tr>
<td>Prior treatment lines</td>
<td>5</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>CAR-T infusion</td>
<td>FEB2021</td>
<td>MAR2021</td>
<td>MAR2021</td>
</tr>
<tr>
<td>DLTs</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>AEs ≥ grade 3*</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>CAR-T engraftment</td>
<td>9x (days 3-17)</td>
<td>&gt;700x (days 3-24)</td>
<td>90x (days 3-10)</td>
</tr>
</tbody>
</table>

First dose level was well tolerated
- AEs Mild to Moderate & Transient
- No AEs ≥ grade 3 and no DLTs

CAR-T detectable across different tumor types
- Robust engraftment in all patients,
  - Follow-up days 3-24 for patient #1 and #2, and days 3-10 for patient #3 post CAR-T cell transfer

Tumor Reduction in Patient #2:
- 19.7% shrinkage of tumor (RECIST 1.1)

---

CR, PR, SD, PD: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease;
LD, lymphodepletion; FIGO, International Federation of Gynecology and Obstetrics; CLDN6, Claudin-6; AE, adverse event; CAR-T, chimeric antigen receptor engineered T cells

* Suspected to be related to drug product

[Diagram showing CAR-T engraftment and tumor reduction]
BNT221: NEO-STIM® Personalized Neoantigen-targeted Adoptive Cell Therapy

Addresses limitations of TIL cell therapy approaches

• T cells induced from peripheral blood (NEO-STIM)
  • No gene engineering or viral vectors
• Targets each patient’s personal tumor neoantigens
• Multiple specific CD8+ and CD4+ T cell populations that are functional and have a favorable phenotype
• First patient dosed in Phase 1 trial in anti-PD-1 experienced unresectable stage III or IV melanoma

BNT221 cells specifically recognize autologous tumor

TIL, tumor-infiltrating lymphocyte
# Agenda

## Overview and business outlook

## Deeper dive on our key programs

- COVID-19 vaccine program (project “Lightspeed”)
- mRNA vaccines – FixVac and iNeST
- Antibodies
- Cell Therapies – CARVac and NEO-STIM T cell therapy
- Small Molecule Immunomodulators
- RiboCytokines
BNT411: First Data Expected in 2H 2021

- BNT411 is an intravenously administered small molecule TLR7 (toll-like receptor 7) agonist
- Engineered for high potency and high TLR7 receptor-selectivity at the therapeutically active dose range
- Activation of both adaptive and innate immune system has been observed, in particular in combination with cytotoxic therapies and CPIs
- Type 1 interferon-dominated release of cytokines and chemokines and potent stimulation of antigen-specific CD8+ T cells, B cells and innate immune cells such as NK cells and macrophages
- Expected to have therapeutic potential across various solid tumor indications
- Phase 1/2a clinical trial as a mono and combination therapy ongoing

Study design:
- Phase 1/2, first-in-human, open-label, dose-escalation trial
- Evaluation of safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BNT411 as a monotherapy in patients with solid tumors and in combination with atezolizumab, carboplatin and etoposide in patients with chemotherapy-naïve extensive-stage small cell lung cancer (ES-SCLC)
- Enrollment: ~60 participants
Overview and business outlook

Deeper dive on our key programs

- COVID-19 vaccine program (project “Lightspeed”)
- mRNA vaccines – FixVac and iNeST
- Antibodies
- Cell Therapies – CARVac and NEO-STIM T cell therapy
- Small Molecule Immunomodulators
- RiboCytokines
RiboCytokines: Designed to Overcome Limitations of Recombinant Cytokine Therapy

Cytokines encoded by mRNA: A novel therapeutic concept

Systemic delivery with minimal immunogenicity
- Backbone optimized and nucleoside-modified mRNA encoding cytokine fused to human albumin
- Liver-targeting LNP formulation with intravenous delivery
- Encoded cytokines translated within cells

Designed for optimized safety, tolerability and dosing
- Prolonged serum half-life
- High bioavailability
- Lower and less frequent dosing
- Lower toxicity

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Indication</th>
<th>Pre-clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>BNT151 (modified IL-2)</td>
<td>Solid Tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BNT152+153 (IL-7 + IL-2)</td>
<td>Solid Tumors</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

LNP, lipid nanoparticle; PK, pharmacokinetic; IL-2, Interleukin-2; IL7, Interleukin-7; UTR, untranslated region
RiboCytokine® is a registered trademark of BioNTech
RiboCytokines: A Tailored Approach to T Cell Regulation and Stimulation

IL-2 supports differentiation, proliferation, survival and effector functions of T cells

**BNT151**

mRNA encoding sequence-modified IL-2 variant

- Sequence modification that weakens binding to IL-2Rα (CD25)
- Designed to stimulate naïve and effector T cells with low to no expression of IL-2Rα (CD25<sub>low/neg</sub>)
- Stimulates anti-tumor effector cells without extensively triggering immunosuppressive regulatory T cells

**BNT152 + 153**

mRNAs encoding IL-2 and IL-7

BNT153 (IL-2)
- Stimulates recently activated anti-tumor T cells and regulatory T cells

BNT152 (IL-7)
- Sensitizes effector T cells to IL2
- Controls fraction of immunosuppressive regulatory T cells

Combination with anti-PD-1/PD-L1 therapy

Combination with RNA vaccine

↑ T cell proliferation
↑ T cell survival
↑ T cell effector function
BNT151: Open-label, Multicenter Phase 1/2, First-in-human Trial

Part 1: Monotherapy Dose Escalation

Multiple solid tumors
- Up to 54 patients
- Enrollment and screening period of 13 months

Evaluation of dose escalation, safety, pharmacokinetics and pharmacodynamics of BNT151 with expansion cohorts in multiple solid tumor indications.

Part 2: Combination Therapy Expansions

Part 2a
- Abbreviated dose escalation OR safety run-in

Part 2b
- Enrollment at RP2D in combination

NSCLC, Non-small Cell Lung Cancer; DL, dose level; MTD, maximum tolerated dose; RP2D, recommended Phase 2 dose; G2, grade 2; DLT, dose limiting toxicity; SoC, Standard of Care; SCCHN, Squamous cell carcinoma of the head and neck; HCC, Hepatocellular carcinoma; RCC, Renal cell carcinoma; TNBC, Triple-negative breast cancer; CPI, checkpoint inhibitor
BNT152 + BNT152: Phase 1 Basket Trial in Patients with Solid Tumors

First-in-Human RiboCytokines Trial Evaluating mRNA-encoded IL-2 + IL-7 with Adaptive Trial Design Informs Dosing

Part 1

Group A
BNT153 monotherapy
dose escalation

Group B
BNT152 monotherapy
dose escalation

Part 2

MTD or MAD

BNT152+153 combination in solid tumors
To initiate after dose escalation is complete for both groups A and B in Part 1

Open-label, Phase 1 dose escalation study
Safety, PK, PD and anti-tumor activity of BNT152+153 in solid tumors

BNT152: IL-7
BNT153: IL-2

Primary Endpoints
- Occurrence of TEAEs
- Dose reduction or discontinuation due to TEAEs
- Occurrence of dose limiting toxicities

Secondary Endpoints
- ORR
- DCR
- DOR

IL-2, Interleukin-2; IL-7, Interleukin-7; MTD, maximum tolerated dose; MAD, maximum administered dose; OBD, optimal biologic dose; PK, pharmacokinetics; PD, pharmacodynamics

TEAE, treatment emergent adverse events, ORR, overall response rate; DCR, disease control rate; DOR, duration of response